TransMedics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
TransMedics Group (Nasdaq: TMDX), a medical technology company specializing in organ transplant therapy solutions, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team will deliver a presentation on Monday, January 13, 2025, at 2:15 p.m. PST (5:15 p.m. EST).
TransMedics, which focuses on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, will make the presentation available through a live and archived webcast on their investor relations website. Interested parties can access both the presentation and the company's standard investor presentation at https://investors.transmedics.com/.
TransMedics Group (Nasdaq: TMDX), un'azienda di tecnologia medica specializzata in soluzioni per la terapia del trapianto d'organo, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. Il team di gestione dell'azienda presenterà una relazione lunedì 13 gennaio 2025, alle 14:15 PST (17:15 EST).
TransMedics, che si concentra sulla trasformazione della terapia del trapianto d'organo per i pazienti con insufficienza terminale polmonare, cardiaca e epatale, renderà disponibile la presentazione tramite un webcast in diretta e archiviato sul proprio sito web dedicato alle relazioni con gli investitori. Le parti interessate possono accedere sia alla presentazione che alla presentazione standard per gli investitori dell'azienda su https://investors.transmedics.com/.
TransMedics Group (Nasdaq: TMDX), una empresa de tecnología médica especializada en soluciones para la terapia de trasplante de órganos, ha anunciado su participación en la 43ª Conferencia Anual J.P. Morgan Healthcare. El equipo directivo de la empresa realizará una presentación el lunes 13 de enero de 2025, a las 2:15 p.m. PST (5:15 p.m. EST).
TransMedics, que se centra en transformar la terapia de trasplante de órganos para pacientes con fallo pulmonar, cardíaco y hepático en etapa terminal, hará disponible la presentación a través de una transmisión web en vivo y archivada en su sitio web de relaciones con inversionistas. Las partes interesadas pueden acceder tanto a la presentación como a la presentación estándar para inversionistas de la empresa en https://investors.transmedics.com/.
TransMedics Group (Nasdaq: TMDX)는 장기 이식 치료 솔루션을 전문으로 하는 의료 기술 회사로, 제43회 연례 JP모건 헬스케어 회의에 참여한다고 발표했습니다. 회사 경영진은 2025년 1월 13일 월요일 오후 2시 15분 PST (오후 5시 15분 EST)에 발표를 진행할 예정입니다.
말기 폐, 심장 및 간 기능 부전을 앓고 있는 환자를 위한 장기 이식 치료 혁신에 집중하는 TransMedics는 투자자 관계 웹사이트를 통해 생중계 및 아카이브 된 웹캐스트로 발표를 제공합니다. 관심 있는 분들은 https://investors.transmedics.com/에서 발표와 회사의 표준 투자자 발표를 모두 접근할 수 있습니다.
TransMedics Group (Nasdaq: TMDX), une entreprise de technologie médicale spécialisée dans les solutions de thérapie de transplantation d'organes, a annoncé sa participation à la 43ème Conférence Annuelle J.P. Morgan Healthcare. L'équipe de direction de l'entreprise présentera une intervention le lundi 13 janvier 2025, à 14h15 PST (17h15 EST).
TransMedics, qui se concentre sur la transformation de la thérapie de transplantation d'organes pour les patients atteints d'insuffisance pulmonaire, cardiaque et hépatique terminale, mettra à disposition la présentation via un webinaire en direct et archivé sur son site web des relations investisseurs. Les parties intéressées peuvent accéder à la fois à la présentation et à la présentation standard pour les investisseurs de l'entreprise sur https://investors.transmedics.com/.
TransMedics Group (Nasdaq: TMDX), ein Medizintechnikunternehmen, das sich auf Lösungen für die Organtransplantation spezialisiert hat, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Conference bekanntgegeben. Das Management-Team des Unternehmens wird am Montag, den 13. Januar 2025, um 14:15 Uhr PST (17:15 Uhr EST) eine Präsentation halten.
TransMedics, das sich auf die Transformation der Organtransplantationstherapie für Patienten mit terminaler Lungen-, Herz- und Leberinsuffizienz konzentriert, wird die Präsentation über ein Live- und ein archiviertes Webcast auf seiner Investor-Relations-Website zur Verfügung stellen. Interessierte Parteien können sowohl auf die Präsentation als auch auf die Standardinvestorenpräsentation des Unternehmens unter https://investors.transmedics.com/ zugreifen.
- None.
- None.
Event: 43rd Annual J.P. Morgan Healthcare Conference
Date: Monday, January 13, 2025
Time: 2:15 p.m. PST
A live and archived webcast of the presentation will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/. The Company's standard investor presentation is also available through this link.
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in
Investor Contact:
Brian Johnston
Laine Morgan
332-895-3222
Investors@transmedics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-participate-in-the-43rd-annual-jp-morgan-healthcare-conference-302338418.html
SOURCE TransMedics Group, Inc.
FAQ
When is TransMedics (TMDX) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch TransMedics' (TMDX) J.P. Morgan Healthcare Conference presentation?
What medical technologies does TransMedics (TMDX) specialize in?
Which annual healthcare conference will TransMedics (TMDX) attend in January 2025?
